core binding factor acute myeloid leukemia (Cancer)
Information
- Disease name
- core binding factor acute myeloid leukemia
- Disease ID
- DOID:0080796
- Description
- "An acute myeloid leukemia that is characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis." [url:https\://pubmed.ncbi.nlm.nih.gov/26980726/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01238211 | Completed | Phase 2 | Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | December 14, 2010 | March 15, 2021 |
| NCT05821738 | Recruiting | Phase 2 | Avapritinib in CBF-AML With KIT Mutations | June 1, 2022 | December 31, 2025 |
| NCT06316960 | Recruiting | Phase 2 | Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation | March 2024 | March 2027 |
| NCT05404516 | Unknown status | Phase 2 | Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML | January 1, 2020 | December 31, 2023 |
- Disase is a (Disease Ontology)
- DOID:9119
- Cross Reference ID (Disease Ontology)
- NCI:C122688